MannKind (MNKD) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.01
- Estimate
- $0.02
- Surprise
- -157.1%
- Revenue (period 2026-06-30)
- $109.4M
- Score at report (before → after)
- 5.6 → 5.8/10
Revenue source: xbrl.
How the report landed
MannKind (MNKD) reported a wider loss than forecast — adjusted EPS of -$0.01 against the $0.02 estimate (a 157.1% shortfall). TrendMatrix's engine moved from Buy (Wait) (5.6/10) to Sell at 5.8/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MNKD Sell at 6.2/10.
0 of the last 4 quarters beat the estimate; this quarter's -157.1% surprise compares with a -264.2% four-quarter average. Next scheduled report: 2027-02-25.
What argues against it
- Concentration risk — Supplier: Amphastar (sole insulin supplier for Afrezza)
- Quality below floor (3.8 < 4.0)
- Value-trap signals (3/5): Margin compression (op margin -900.1%), Material insider selling (3 sells, 0.18% of cap), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.96
- Price target
- $7.25
- Stop
- $3.68
- Upside to target
- +83.3%
- Reward-to-risk
- 5.5:1
Risk check: RSI 71 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
MNKD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.33B
- P/E (fwd)
- 26.2
- 52-week range
- $2.23–$6.51
- Off 52-week high
- 39.2%
- RSI (14)
- 71
- Volume vs avg
- 0.85×
- Score today
- 6.2/10